What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
Stephen Jan, Tim Usherwood, Jo Brien, David Peiris, John Rose, Noel Hayman, Kirsten Howard, Julie Redfern, Tracey Laba, Alan Cass, Anushka Patel
Background: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills ('polypills') potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy.
Methods/design: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour.
Ethics and dissemination: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations.
BMJ Open
https://doi.org/10.1136/bmjopen-2011-000372
10.1136/bmjopen-2011-000372Licence: Other
5372838-oaFinal published version, 164 KBLicence: Other
Dive into the research topics of 'What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study'. Together they form a unique fingerprint.
Treatment Adherence and Compliance Medicine & Life Sciences 100%
Cardiovascular Diseases Medicine & Life Sciences 63%
Ethics Medicine & Life Sciences 59%
Health Services Research Medicine & Life Sciences 33%
Joints Medicine & Life Sciences 20%
Jan, S., Usherwood, T., Brien, J., Peiris, D., Rose, J., Hayman, N., Howard, K., Redfern, J., Laba, T., Cass, A., & Patel, A. (2011). What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. BMJ Open, 1(2), 1-8. [e000372]. https://doi.org/10.1136/bmjopen-2011-000372
Jan, Stephen ; Usherwood, Tim ; Brien, Jo et al. / What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. In: BMJ Open. 2011 ; Vol. 1, No. 2. pp. 1-8.
@article{bad50d8045c34a1aa29d43cf014cff33,
title = "What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study",
abstract = "Background: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills ({\textquoteleft}polypills{\textquoteright}) potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy.Methods/design: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour.Ethics and dissemination: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations.",
author = "Stephen Jan and Tim Usherwood and Jo Brien and David Peiris and John Rose and Noel Hayman and Kirsten Howard and Julie Redfern and Tracey Laba and Alan Cass and Anushka Patel",
doi = "10.1136/bmjopen-2011-000372",
journal = "BMJ Open",
publisher = "British Medical Journal Publishing Group (BMJ Publishing)",
Jan, S, Usherwood, T, Brien, J, Peiris, D, Rose, J, Hayman, N, Howard, K, Redfern, J, Laba, T, Cass, A & Patel, A 2011, 'What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study', BMJ Open, vol. 1, no. 2, e000372, pp. 1-8. https://doi.org/10.1136/bmjopen-2011-000372
What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. / Jan, Stephen; Usherwood, Tim; Brien, Jo et al.
In: BMJ Open, Vol. 1, No. 2, e000372, 2011, p. 1-8.
T1 - What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
AU - Jan, Stephen
AU - Usherwood, Tim
AU - Brien, Jo
AU - Peiris, David
AU - Rose, John
AU - Hayman, Noel
AU - Howard, Kirsten
AU - Redfern, Julie
AU - Laba, Tracey
AU - Cass, Alan
AU - Patel, Anushka
N2 - Background: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills ('polypills') potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy.Methods/design: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour.Ethics and dissemination: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations.
AB - Background: Significant gaps exist between guidelines-recommended therapies for cardiovascular disease prevention and current practice. Fixed-dose combination pills ('polypills') potentially improve adherence to therapy. This study is a preference study undertaken in conjunction with a clinical trial of a polypill and seeks to examine the underlying reasons for variations in treatment adherence to recommended therapy.Methods/design: A preference study comprising: (1) Discrete Choice Experiment for patients; and (2) qualitative study of patients and providers. Both components will be conducted on participants in the trial. A joint model combining the observed adherence in the clinical trial (revealed preference) and the Discrete Choice Experiment data (stated preference) will be estimated. Estimates will be made of the marginal effect (importance) of each attribute on overall choice, the extent to which respondents are prepared to trade-off one attribute for another and predicted values of the level of adherence given a fixed set of attributes, and contextual and socio-demographic characteristics. For the qualitative study, a thematic analysis will be used as a means of exploring in depth the preferences and ultimately provide important narratives on the experiences and perspectives of individuals with regard to adherence behaviour.Ethics and dissemination: Primary ethics approval was received from Sydney South West Area Health Service Human Research Ethics Committee (Royal Prince Alfred Hospital zone). In addition to usual scientific forums, the findings will be reported back to the communities involved in the studies through site-specific reports and oral presentations.
U2 - 10.1136/bmjopen-2011-000372
DO - 10.1136/bmjopen-2011-000372
JO - BMJ Open
JF - BMJ Open
M1 - e000372
Jan S, Usherwood T, Brien J, Peiris D, Rose J, Hayman N et al. What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study. BMJ Open. 2011;1(2):1-8. e000372. https://doi.org/10.1136/bmjopen-2011-000372